Over the past 21 years, more than 35,000 children ages 17 and younger have been transplant recipients in the U.S. Before preventative measures were taken to reduce the risk of infection, CMV among pediatric transplant patients was found in 26 percent of thoracic organ and 22 percent of kidney recipients.
New Pediatric Indication in Organ Transplant Patients
Valcyte, the leading anti-CMV agent, is now approved for the prevention of CMV disease in pediatric patients 4 months to 16 years of age who have undergone kidney or heart transplantation and who are at high risk for developing CMV disease. The safety and efficacy of Valcyte has not been established in the prevention of CMV disease in pediatric solid organ transplant patients under 4 months of age or for the treatment of congenital CMV.
Source: roche